𝔖 Bobbio Scriptorium
✦   LIBER   ✦

S25.1: Alternative designs for phase II MS trials

✍ Scribed by Karina Eder; Susanne Menzler; Ulrike Held; Martin Daumer; Helmut Küchenhoff; Albrecht Neiß

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
76 KB
Volume
46
Category
Article
ISSN
0323-3847

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimal three-stage designs for phase II
Optimal three-stage designs for phase II cancer clinical trials
✍ T. Timothy Chen 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

The objective of a phase II cancer clinical trial is to screen a treatment that can produce a similar or better response rate compared to the current treatment results. This screening is usually carried out in two stages as proposed by Simon. For ineffective treatment, the trial should terminate at

Optimal flexible designs in phase II cli
Optimal flexible designs in phase II clinical trials
✍ T. Timothy Chen; Tie-Hua Ng 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

In the conduct of a phase II cancer clinical trial, patients usually enter in two stages. If the response rate from the first stage is low, then the study terminates. Within various two-stage designs, Simon proposed the optimal and minimax criteria. In the co-operative group setting, practical consi

Optimal multi-stage designs for a phase
Optimal multi-stage designs for a phase II trial that permits one dose escalation
✍ John J. Hanfelt 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

Simon's optimal two-stage design is widely used to conduct single-dose phase II clinical trials. We extend this basic methodology to the situation where the researcher desires to test an experimental drug for activity at a low dose level, but is willing to increase the dose part-way through the tria

Granulocyte-macrophage–colony stimulatin
Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f